Literature DB >> 32600532

Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma.

Kyrollis Attalla1, Stanley Weng1, Martin H Voss1, A Ari Hakimi2.   

Abstract

In the preceding two decades, several milestones have been reached in the management of patients with metastatic renal cell carcinoma (mRCC), including the development of novel targeted agents paralleling an increased understanding of the molecular biology of this disease process. Recently, a renewed enthusiasm for immunotherapy in the form of immune checkpoint blockade has resulted in significant strides in the treatment of mRCC. Despite these advances, treatment remains challenging for clinicians, and only modest survival benefits are observed with current treatment paradigms. The risk-stratification tools and investigated predictive and prognostic biomarkers in patients with mRCC are detailed in this review.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunotherapy; Metastatic renal cell carcinoma; Predictive biomarker; Prognostic biomarker; Risk assessment; Targeted therapy

Mesh：

Substances：

Year:  2020        PMID： 32600532      PMCID： PMC8327324          DOI： 10.1016/j.ucl.2020.04.002

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN： 0094-0143            Impact factor:   2.241


  60 in total

Review 1.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

2.  A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing.

Authors:  Deng Pan; Aya Kobayashi; Peng Jiang; Lucas Ferrari de Andrade; Rong En Tay; Adrienne M Luoma; Daphne Tsoucas; Xintao Qiu; Klothilda Lim; Prakash Rao; Henry W Long; Guo-Cheng Yuan; John Doench; Myles Brown; X Shirley Liu; Kai W Wucherpfennig
Journal:  Science       Date:  2018-01-04       Impact factor: 47.728

3.  The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.

Authors:  Jenny J Ko; Wanling Xie; Nils Kroeger; Jae-Lyun Lee; Brian I Rini; Jennifer J Knox; Georg A Bjarnason; Sandy Srinivas; Sumanta K Pal; Takeshi Yuasa; Martin Smoragiewicz; Frede Donskov; Ravindran Kanesvaran; Lori Wood; D Scott Ernst; Neeraj Agarwal; Ulka N Vaishampayan; Sun-Young Rha; Toni K Choueiri; Daniel Y C Heng
Journal:  Lancet Oncol       Date:  2015-02-12       Impact factor: 41.316

4.  Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.

Authors:  Martin H Voss; Albert Reising; Yuan Cheng; Parul Patel; Mahtab Marker; Fengshen Kuo; Timothy A Chan; Toni K Choueiri; James J Hsieh; A Ari Hakimi; Robert J Motzer
Journal:  Lancet Oncol       Date:  2018-11-08       Impact factor: 41.316

5.  Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial.

Authors:  Brian I Rini; Thomas Powles; Michael B Atkins; Bernard Escudier; David F McDermott; Cristina Suarez; Sergio Bracarda; Walter M Stadler; Frede Donskov; Jae Lyun Lee; Robert Hawkins; Alain Ravaud; Boris Alekseev; Michael Staehler; Motohide Uemura; Ugo De Giorgi; Begoña Mellado; Camillo Porta; Bohuslav Melichar; Howard Gurney; Jens Bedke; Toni K Choueiri; Francis Parnis; Tarik Khaznadar; Alpa Thobhani; Shi Li; Elisabeth Piault-Louis; Gretchen Frantz; Mahrukh Huseni; Christina Schiff; Marjorie C Green; Robert J Motzer
Journal:  Lancet       Date:  2019-05-09       Impact factor: 79.321

6.  PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Authors:  Toni K Choueiri; Sabina Signoretti; Abdallah Flaifel; Wanling Xie; David A Braun; Miriam Ficial; Ziad Bakouny; Amin H Nassar; Rebecca B Jennings; Bernard Escudier; Daniel J George; Robert J Motzer; Michael J Morris; Thomas Powles; Evelyn Wang; Ying Huang; Gordon J Freeman
Journal:  Clin Cancer Res       Date:  2019-08-01       Impact factor: 12.531

7.  External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri
Journal:  Lancet Oncol       Date:  2013-01-09       Impact factor: 41.316

8.  Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.

Authors:  Michael M Vickers; Hulayel Al-Harbi; Toni K Choueiri; Christian Kollmannsberger; Scott North; Mary MacKenzie; Jennifer J Knox; Brian I Rini; Daniel Y C Heng
Journal:  Clin Genitourin Cancer       Date:  2013-05-15       Impact factor: 2.872

9.  The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database.

Authors:  Ulka Vaishampayan; Hema Vankayala; Fawn D Vigneau; William Quarshie; Brenda Dickow; Supraja Chalasani; Kendra Schwartz
Journal:  Clin Genitourin Cancer       Date:  2013-09-28       Impact factor: 2.872

10.  Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.

Authors:  M I Carlo; B Manley; S Patil; K M Woo; D T Coskey; A Redzematovic; M Arcila; M Ladanyi; W Lee; Y B Chen; C H Lee; D R Feldman; A A Hakimi; R J Motzer; J J Hsieh; M H Voss
Journal:  Kidney Cancer       Date:  2017-07-26
View more
  8 in total

Review 1.  Autophagy as a Vital Therapy Target for Renal Cell Carcinoma.

Authors:  Ying-Hua He; Guo Tian
Journal:  Front Pharmacol       Date:  2021-02-10       Impact factor: 5.810

2.  Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.

Authors:  Yuqin Qiu; Xiaogang Wang; Zhenjia Fan; Shanhui Zhan; Xin Jiang; Jinchang Huang
Journal:  Immun Inflamm Dis       Date:  2021-08-25

3.  Identification and Validation of a Ferroptosis-Related Long Non-Coding RNA (FRlncRNA) Signature to Predict Survival Outcomes and the Immune Microenvironment in Patients With Clear Cell Renal Cell Carcinoma.

Authors:  Zhongbao Zhou; Zhenpeng Yang; Yuanshan Cui; Shuai Lu; Yongjin Huang; Xuanyan Che; Liqing Yang; Yong Zhang
Journal:  Front Genet       Date:  2022-03-08       Impact factor: 4.599

4.  Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma.

Authors:  Ziqi Gong; Xiaowen Wu; Qian Guo; Haizhen Du; Fenghao Zhang; Yan Kong
Journal:  Genes (Basel)       Date:  2022-07-20       Impact factor: 4.141

5.  Identification of epigenetic dysregulation gene markers and immune landscape in kidney renal clear cell carcinoma by comprehensive genomic analysis.

Authors:  Linli Xie; Shuang Wu; Rong He; Sisi Li; Xiaodan Lai; Zhe Wang
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

6.  The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis.

Authors:  Sara Elena Rebuzzi; Alessio Signori; Marco Stellato; Daniele Santini; Marco Maruzzo; Ugo De Giorgi; Paolo Pedrazzoli; Luca Galli; Paolo Andrea Zucali; Emanuela Fantinel; Claudia Carella; Giuseppe Procopio; Michele Milella; Francesco Boccardo; Lucia Fratino; Roberto Sabbatini; Riccardo Ricotta; Stefano Panni; Francesco Massari; Mariella Sorarù; Matteo Santoni; Alessio Cortellini; Veronica Prati; Hector Josè Soto Parra; Francesco Atzori; Marilena Di Napoli; Orazio Caffo; Marco Messina; Franco Morelli; Giuseppe Prati; Franco Nolè; Francesca Vignani; Alessia Cavo; Giandomenico Roviello; Miguel Angel Llaja Obispo; Camillo Porta; Sebastiano Buti; Giuseppe Fornarini; Giuseppe Luigi Banna
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

Review 7.  Isolated Pancreatic Metastases of Renal Cell Cancer: Genetics and Epigenetics of an Unusual Tumour Entity.

Authors:  Franz Sellner; Sabine Thalhammer; Martin Klimpfinger
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

8.  Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study).

Authors:  Sara Elena Rebuzzi; Alessio Signori; Giuseppe Luigi Banna; Marco Maruzzo; Ugo De Giorgi; Paolo Pedrazzoli; Andrea Sbrana; Paolo Andrea Zucali; Cristina Masini; Emanuele Naglieri; Giuseppe Procopio; Sara Merler; Laura Tomasello; Lucia Fratino; Cinzia Baldessari; Riccardo Ricotta; Stefano Panni; Veronica Mollica; Maria Sorarù; Matteo Santoni; Alessio Cortellini; Veronica Prati; Hector Josè Soto Parra; Marco Stellato; Francesco Atzori; Sandro Pignata; Carlo Messina; Marco Messina; Franco Morelli; Giuseppe Prati; Franco Nolè; Francesca Vignani; Alessia Cavo; Giandomenico Roviello; Francesco Pierantoni; Chiara Casadei; Melissa Bersanelli; Silvia Chiellino; Federico Paolieri; Matteo Perrino; Matteo Brunelli; Roberto Iacovelli; Camillo Porta; Sebastiano Buti; Giuseppe Fornarini
Journal:  Ther Adv Med Oncol       Date:  2021-05-18       Impact factor: 8.168
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.